Learn About Alveolar Soft Part Sarcoma

What is the definition of Alveolar Soft Part Sarcoma?
Alveolar soft part sarcoma (ASPS) is a rare, slow-growing soft tissue sarcoma. Although it has been described in a variety of locations, it most commonly develops on the lower extremities in adults and in the head and neck region of children. ASPS generally presents as a soft, pain-less lump that is often not associated with any additional signs and symptoms. In many cases, the condition is not diagnosed until the affected person develops symptoms of metastasis to other sites such as the lungs, bones, central nervous system and/or liver. The underlying cause of ASPS is poorly understood. Most cases occur sporadically in people with no family history of the condition.
Save information for later
Sign Up
What are the alternative names for Alveolar Soft Part Sarcoma?
  • Alveolar soft part sarcoma
  • ASPS
Who are the top Alveolar Soft Part Sarcoma Local Doctors?
Learn about our expert tiers
Learn more
What are the latest Alveolar Soft Part Sarcoma Clinical Trials?
A Phase II Trial In Which Patients With Metastatic Alveolar Soft Part Sarcoma Are Randomized to Either Sunitinib or Cediranib Monotherapy, With Cross-Over at Disease Progression

Background: Alveolar soft part sarcoma (ASPS) is a rare, highly vascular tumor accounting for less than 1% of soft tissue sarcomas. There is no effective systemic treatment for patients with metastatic ASPS. Little is known with regards to relevant molecular markers as potential therapeutic targets. Cediranib (AZD2171) and sunitinib (SU011248), oral small molecule inhibitors of VEGF receptor tyrosine kinases,...

Match to trials
Find the right clinical trials for you in under a minute
Get started
A Phase 2 Study of Anti-PD-L1 Antibody (Atezolizumab) in Alveolar Soft Part Sarcoma

Summary: This phase II trial studies how well atezolizumab or atezolizumab plus bevacizumab works in treating patients with alveolar soft part sarcoma that has not been treated, has spread from where it started to other places in the body (advanced) and cannot be removed by surgery (unresectable). Atezolizumab works by unblocking the immune system, allowing the immune system cells to recognize and then att...

Who are the sources who wrote this article ?

Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center

What are the Latest Advances for Alveolar Soft Part Sarcoma?
Alveolar soft part sarcoma: progress toward improvement in survival? A population-based study.
Durvalumab plus tremelimumab in advanced or metastatic soft tissue and bone sarcomas: a single-centre phase 2 trial.
Tired of the same old research?
Check Latest Advances
Phase II Study of TQB2450, a Novel PD-L1 Antibody, in Combination with Anlotinib in Patients with Locally Advanced or Metastatic Soft Tissue Sarcoma.